Thomas Mencken

Discovery of 7-Methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1<i>H</i>-indol-5-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (GSK2606414), a Potent and Selective First-in-Class Inhibitor of Protein Kinase R (PKR)-like Endoplasmic Reticulum Kinase (PERK)

Jeffrey M. Axten, Jesús R. Medina, Yanhong Feng et al. · Journal of Medicinal Chemistry · 2012 · 619 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +13

Discovery of GSK2656157: An Optimized PERK Inhibitor Selected for Preclinical Development

Jeffrey M. Axten, Stuart P. Romeril, Arthur Y. L. Shu et al. · ACS Medicinal Chemistry Letters · 2013 · 230 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16

A Whole-Molecule Immunocapture LC–MS Approach for The <i>In Vivo</i> Quantitation of Biotherapeutics

John F. Kellie, Jonathan Kehler, Thomas Mencken et al. · Bioanalysis · 2016 · 45 citations

Pharmacy, Pharmaceutical Analysis, Pharmacology +14

False-Positive Immunochemical Screen for Methadone Attributable to Metabolites of Verapamil

Mark Lichtenwalner, Thomas Mencken, Robert Tully et al. · Clinical Chemistry · 1998 · 31 citations · Full text

Pharmacy, Pharmaceutical Analysis, Pharmacology +15

Pharmacokinetics and Brain Penetration of Casopitant, a Potent and Selective Neurokinin-1 Receptor Antagonist, in the Ferret

Elisabeth A. Minthorn, Thomas Mencken, Andrew G. King et al. · Drug Metabolism and Disposition · 2008 · 25 citations

Medicine, Pharmacokinetics, Pharmacology +12